ETCISO Announces the 8th Annual Conclave 2025: Redefining Cyber Leadership for the Digital Age
NEW DELHI, Aug. 4, 2025 /PRNewswire/ -- As India grapples with a…
Solace Announces Availability of Solace Agent Mesh in the new AWS Marketplace AI Agents and Tools Category
OTTAWA, ON, July 17, 2025 /PRNewswire/ -- Solace, the leader in powering…
Manipal Hospital Yeshwanthpur Leads the Charge as Heart Attacks in Young Indians Reach Crisis Levels
BENGALURU, India, July 17, 2025 /PRNewswire/ -- India is witnessing an alarming…
ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles
A new international study presented today at the 41st Annual Meeting of…
NETMARBLE OPENS GLOBAL PRE-REGISTRATION FOR NEW MASSIVE PET BRAWL RPG STONEAGE: PET WORLD
SEOUL, South Korea, June 18, 2025 /PRNewswire/ -- Netmarble, a leading developer…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
Solace Announces Paul Fitzpatrick as Chief Marketing and Business Development Officer
OTTAWA, ON, June 12, 2025 /PRNewswire/ -- Solace, the leader in powering…
Discover the Superhero Within: New Book ‘Stories with Purpose’ by Laura G. Patac Helps Readers Turn Life’s Challenges into Purpose
What if your favorite superhero story was already unfolding, in your own…